$0.01
0.00 (-12.00%)
Open$0.01
Previous Close$0.01
Day High$0.01
Day Low$0.01
52W High$2.33
52W Low—
Volume—
Avg Volume362.0K
Market Cap394.4K
P/E Ratio—
EPS$-3.78
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+249,445.5% upside
Current
$0.01
$0.01
Target
$21.96
$21.96
$14.05
$21.96 avg
$26.87
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.36M | 1.98M | 5.52M |
| Net Income | -256,638,380 | -193,933,284 | -589,967 |
| Profit Margin | -10,887.4% | -10,343.0% | -10.7% |
| EBITDA | -184,176,306 | -146,908,052 | -924,468 |
| Free Cash Flow | — | — | -774,673 |
| Rev Growth | +19.1% | +19.1% | -1.7% |
| Debt/Equity | 1.21 | 1.21 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |